Comparative Pharmacology
Head-to-head clinical analysis: MELPHALAN versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELPHALAN versus TREANDA.
MELPHALAN vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melphalan is an alkylating agent that forms interstrand crosslinks with DNA, inhibiting DNA replication and transcription, leading to cell death.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
Melphalan 0.25 mg/kg/day orally for 4 consecutive days, repeated every 4-6 weeks; or 16 mg/m² intravenously over 15-20 minutes at 2-week intervals for 4 doses.
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateMelphalan + Digoxin
"Melphalan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMelphalan + Digitoxin
"Melphalan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMelphalan + Deslanoside
"Melphalan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMelphalan + Acetyldigitoxin
"Melphalan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 1.5-2 hours (IV); prolonged in renal impairment (up to 3-4 hours).
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal: 10-15% unchanged; hepatic metabolism (20-30%) with biliary excretion of metabolites; fecal: <5%.
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category D/X
Category C
Alkylating Agent
Alkylating Agent